Antibodies News and Research

RSS

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

Eisai Corporation of North America, its U.S. subsidiary, MGI PHARMA, INC., and Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

4 Mar 2008

New inexpensive test for malaria detection

ETH Zurich professor Peter Seeberger has been working on a sugar-based malaria vaccine for years.

4 Mar 2008

Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells

Early detection of tumors is one of the Holy Grails of cancer research, an achievement that would greatly improve cancer therapy and prognosis. Two new reports describe different but promising approaches to solving this problem.

3 Mar 2008

Arsenic used to label antibodies for the detection of tumors

Arsenic linked to a drug that binds to the blood vessels of cancerous tumors provides a powerful imaging agent that could one day allow physicians to detect hard-to-find tumors and more closely monitor cancer's response to therapy, researchers at UT Southwestern Medical Center have found.

3 Mar 2008

New global study of targeted therapies for breast cancer

Two targeted medications designed to treat an aggressive form of breast cancer are being tested in a new study involving 8,000 participants in 50 countries across six continents -- a clinical trial that investigators hope will provide a new model for global cancer research.

1 Mar 2008

Gene expression differences between Europeans and Africans affect response to drugs, infections

Differences in gene expression levels between people of European versus African ancestry can affect how each group responds to certain drugs or fights off specific infections, report researchers from the University of Chicago Medical Center and the Expression Research Laboratory at Affymetrix Inc. of Santa Clara, CA.

28 Feb 2008

Rresearch may lead to a better flu vaccine

New research from a scientist at the University of Tennessee, Knoxville, has uncovered information that may someday lead to a better flu vaccine.

28 Feb 2008

Scientists devise approach that stops HIV at earliest stage of infection

Their study, which appears this week in the online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), may re-energize attempts to create a preventive/therapeutic vaccine against HIV, say the authors.

28 Feb 2008

Inverted DNA turns quiet developmental gene into a potent driver of t-cell lymphoma

A gene crucial for embryonic development can quickly become a potent cancer promoter in adult mice after a genetic misalignment, according to researchers from Fox Chase Cancer Center, causing white blood cells to become cancerous spontaneously.

28 Feb 2008

Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease?

The association of ABG with thyroid disorders (TD) was first described about 40 years ago.

28 Feb 2008

Nanoemulsion vaccines show increasing promise

A novel technique for vaccinating against a variety of infectious diseases - using an oil-based emulsion placed in the nose, rather than needles - has proved able to produce a strong immune response against smallpox and HIV in two new studies.

27 Feb 2008

Mother's immune system may play role in chilld's autism

The mothers of some autistic children may have made antibodies against their fetuses' brain tissue during pregnancy that crossed the placenta and caused changes that led to autism, suggests research led by Johns Hopkins Children's Center investigators and published in the February issue of the Journal of Neuroimmunology.

26 Feb 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

ImClone Systems enrols first patient in clinical trial of IMC-1121B to treat liver cancer

ImClone Systems Incorporated has announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma (liver cancer).

26 Feb 2008

New large-scale method reveals drug targets

Wellcome Trust Sanger Institute scientists have developed a new large-scale method to identify the interactions between proteins that are a major target for therapeutic intervention.

26 Feb 2008

XYNTHA approved for teatment of hemophilia A by FDA

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE) , announced today that it has received approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis.

22 Feb 2008

New understanding of how big molecules bind will lead to better drugs, synthetic organic materials

Biological and medical research is on the threshold of a new era based on better understanding of how large organic molecules bind together and recognise each other.

22 Feb 2008

New method for detecting HER2 breast cancer

Generations of mothers have served up chicken soup to remedy the common cold, but now the therapeutic fowl may find use in diagnosis as well.

21 Feb 2008

More needs to be done for preemie healthcare

A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthcare system does not place enough emphasis on or dedicate enough resources to preventive healthcare for preemies.

20 Feb 2008

Vaccinex antibody licensed to GlaxoSmithKline

EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

18 Feb 2008

Antibodies News and Research

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

New inexpensive test for malaria detection

Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells

Arsenic used to label antibodies for the detection of tumors

New global study of targeted therapies for breast cancer

Gene expression differences between Europeans and Africans affect response to drugs, infections

Rresearch may lead to a better flu vaccine

Scientists devise approach that stops HIV at earliest stage of infection

Inverted DNA turns quiet developmental gene into a potent driver of t-cell lymphoma

Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease?

Nanoemulsion vaccines show increasing promise

Mother's immune system may play role in chilld's autism

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

ImClone Systems enrols first patient in clinical trial of IMC-1121B to treat liver cancer

New large-scale method reveals drug targets

XYNTHA approved for teatment of hemophilia A by FDA

New understanding of how big molecules bind will lead to better drugs, synthetic organic materials

New method for detecting HER2 breast cancer

More needs to be done for preemie healthcare

Vaccinex antibody licensed to GlaxoSmithKline

Immunology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News